Biotech | August 30, 2021
Vivo Bio Tech enters long-term contract with Bio E
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The company to receive upfront and milestone payments, in addition to royalties
Shanghai Roche Pharmaceuticals and Shanghai KeChow Pharma, entered into a cooperation agreement to improve market access of Zelboraf in China.
The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
A treatment to prevent extreme symptoms and cut hospitalisation
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
The goal for the project is the identification and optimization of anti-viral compounds.
Advances deployment of mRNA technology across vaccines and therapeutics development
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Subscribe To Our Newsletter & Stay Updated
